Kevin S. Sr. Boyle - Sep 1, 2023 Form 4 Insider Report for Alaunos Therapeutics, Inc. (TCRT)

Role: Chief Executive Officer, Director
Signature: /s/ Melinda Lackey, Attorney-in-Fact
Stock symbol: TCRT
Transactions as of: Sep 1, 2023
Transactions value $: -$9,542
Form type: 4
Date filed: 9/5/2023, 05:34 PM
Previous filing: Mar 17, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	TCRT	Common Stock	Sale	-$9.54K	-68K	-7.85%	$0.14	798K	Sep 1, 2023	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id	Content
F1	Represents the sale of shares of Common Stock pursuant to a "sell-to-cover" transaction in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of shares of restricted stock previously granted to the Reporting Person. This sale was effected pursuant to a plan adopted on November 17, 2022 in accordance with Rule 10b5-1 and does not represent a discretionary sale by the reporting person.
F2	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.14 to $0.1424, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Content

Represents the sale of shares of Common Stock pursuant to a "sell-to-cover" transaction in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of shares of restricted stock previously granted to the Reporting Person. This sale was effected pursuant to a plan adopted on November 17, 2022 in accordance with Rule 10b5-1 and does not represent a discretionary sale by the reporting person.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.14 to $0.1424, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.